Morgan Stanley Analyst Raises Gilead Sciences Target Price to $145

Summary

JPMorgan analyst Chris Schott has raised the price target for Gilead Sciences, Inc. (NASDAQ:GILD) from $135 to $145, while maintaining an Overweight rating. Gilead is part of the Renaissance Technologies Portfolio’s 10 Biggest Stocks.MSN

Impact Analysis

So basically, JPMorgan’s analyst Chris Schott is signaling a bullish outlook on Gilead Sciences by raising the price target to $145, up from $135, while keeping an Overweight rating. This move seems to reflect confidence in Gilead’s growth potential, particularly in light of the CDC’s endorsement of its HIV prevention drug, Yeztugo, which could significantly boost market penetration and revenue streams.Tip Ranks However, the technical analysis paints a mixed picture with a long-term uptrend but short-term weakness, as indicated by MACD and RSI signals. The market might be underestimating the impact of institutional investors increasing their stakes, which could provide support for the stock.Market Beat+ 2 The trade here could be to watch for a breakout above the current resistance levels, especially if the fundamentals continue to improve. Keep an eye on insider trading activities, as significant sales by executives could dampen sentiment.Market Beat+ 2